Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Lin, Zhang, Jian-Zhong, Yao, Xu, Gu, Jun, Liu, Quan-Zhong, Zheng, Min, Zhang, Shi-Fa, Xu, Jin-Hua, Li, Cheng-Xin, Cheng, Hao, Guo, Qing, Pan, Wei-Li, Li, Shen-Qiu, Li, Ruo-Yu, Guo, Zai-Pei, Song, Zhi-Qi, Li, Shan-Shan, Dong, Xiu-Qin, Wang, Linda, Fu, Rong, Regnault, Pascaline, Charef, Pascal, Mazur, Rafal, Patekar, Manmath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647502/
https://www.ncbi.nlm.nih.gov/pubmed/33060370
http://dx.doi.org/10.1097/CM9.0000000000001163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647502/
https://www.ncbi.nlm.nih.gov/pubmed/33060370
http://dx.doi.org/10.1097/CM9.0000000000001163

Ejemplares similares